ALNA - Allena Pharmaceuticals EPS misses by $0.05

Allena Pharmaceuticals (ALNA): Q4 GAAP EPS of -$0.24 misses by $0.05.Cash and cash equivalents of $35.04M.“Building on the significant accomplishments of 2020, we are entering 2021 well-positioned to execute on our mission of delivering novel oral biologic medicines to patients with rare and serious metabolic and kidney diseases,” said Louis Brenner, M.D, President and Chief Executive Officer of Allena Pharmaceuticals. “We successfully reinvigorated our global Phase 3 URIROX-2 clinical trial of reloxaliase for the treatment of enteric hyperoxaluria, a life-threatening disease for which there is no currently approved therapy. In addition, we initiated clinical development of ALLN-346 for the treatment of hyperuricemia and gout, our second oral biologic program, further demonstrating the potential broad applicability of our technology platform."Press Release

For further details see:

Allena Pharmaceuticals EPS misses by $0.05